checkAd

     101  0 Kommentare Angion Announces Discontinuation of Phase 2 Trial of ANG-3070 in Patients with Primary Proteinuric Kidney Disease - Seite 3 

    CONTACT: Contact:

David D. Miller
Sr. Director of Corporate Affairs
investors@angion.com


    globenewswire
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors

    Seite 3 von 3
    Verfasst von globenewswire
    Angion Announces Discontinuation of Phase 2 Trial of ANG-3070 in Patients with Primary Proteinuric Kidney Disease - Seite 3 UNIONDALE, N.Y., June 29, 2022 (GLOBE NEWSWIRE) - Angion Biomedica Corp. (NASDAQ:ANGN), a biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases, …